echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > The National Health Insurance Administration issued a letter to investigate the bribery of medicines

    The National Health Insurance Administration issued a letter to investigate the bribery of medicines

    • Last Update: 2020-07-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On June 5, the State Health Insurance Administration (NSS) is seeking comments for the second time on the "Guidelines on the Establishment of a Credit Evaluation System for Pharmaceutical Prices and Recruitment"document guiding ideology shows that relying on drugs and medical supplies tender procurement platform, system integration and trustworthiness commitment, credit rating, graded disposal, credit repair and other mechanisms, the establishment of rights and responsibilitiesCoordinate the joint pharmaceutical price and bidding procurement credit evaluation systemalthough the system of credit evaluation and discipline is no longer new in our daily life, but applicable to the national level of drug prices and recruitment areas, is the first time, this document into the second draft stage, the promotion of fast, strong, it may meet with us in the near futurecompared with the first draft for comments, the Opinion sedative more clear credit evaluation list, breach of trust information report records, credit repair of pharmaceutical enterprises and how to dispose of the accessibility at the same time, more convenient for the implementation and operation of future documentsit is worth noting that the Opinion requires pharmaceutical enterprises to participate in or entrust to participate in the centralized procurement of medicines and medical supplies, platform network, as well as medical insurance fixed-point medical institutions (hereinafter referred to as "medical institutions") for the record procurement, should be centralized procurement agencies, in advance to make a commitment to keep a letterfor pharmaceutical enterprises that have not submitted a commitment, the provincial centralized procurement agencies shall not accept their drug networks, tenders or otherwise sell medicines to medical institutionsfor pharmaceutical companies, the submission of commitments has become a prerequisite for entering the hospital: commitment pricing, marketing, bidding, performance process does not occur in the list of breach of trust list;documents clearly, to all kinds of medical institutions and their staff at all levels of the implementation of "kickbacks" and other forms of commercial bribery, due to price and marketing misconduct by the medical security department inquiries, investigations, interviews, warnings, inspection, pharmaceutical enterprises push, refused to cooperate, can not fully explain the reasons or make false promises and other acts, have entered the list of pharmaceutical prices and recruitment of breach of trust (2020 edition)the relevant departments from the source, including the hiring of personnel, entrusted agents, invisible pharmaceutical companies and agents of credit bundles, once the above-mentioned behavior, will bear the most strictly prohibited access to the market, and included in the "national pharmaceutical prices and recruitment of the risk of enterprise risk warning list" resultsone of the roles of the credit evaluation system is to discipline non-standard enterprises, so the document also provides for the classification of breach of trust responsibility, drug companies to discipline the most strictly prohibited into the market, and quarterly publicity to the community, to accept supervisionAt the same time, the document also encourages local exploration of quantitative credit rating methods, and continuously improve the standardization of credit ratingcompared with the first draft of the draft, the new version of the document deletes the "by the local provincial medical security departments to include it in the scope of combating "fraud insurance", in accordance with the law to recover the enterprise swindle medical insurance funds obtained improper benefitsMeasures, but will be "publicly issued an apology statement, the initiative to remove the product price of the false high space, correct the use of market manipulation to form unreasonable high prices and the initiative to return unreasonable returns" of the expression added to the enterprise's initiative to restore creditto some extent, the relevant departments are intended to play a single enterprise initiative, to give it the opportunity to restore credit, but increased to the public, disclosure of the results of the enterprise rating part, enterprises take the initiative to correct at the same time to accept the supervision of public opinion from all walks of lifethe purpose ofdiscipline is not to simply let an enterprise ban into the market, the deeper significance is to guide the benign development of the industry, so the relevant departments set up a pharmaceutical enterprise credit automatic repair and active repair mechanism, compared to the previous version of the draft, the new version appears more moderate if the the breach of trust behavior exceeds a certain period of time, it will no longer be retroactively included in the scope of credit evaluation, and automatic repair will be realized Encourage pharmaceutical enterprises to take the initiative to repair credit, remind pharmaceutical enterprises before the disposal measures take effect, and give a certain rectification period, as the circumstances, accept that they take practical measures to repair credit during the rectification period, including the termination of related breach of trust, submit compliance rectification reports, publicly issue an apology statement to eliminate adverse effects, remove the false high space in the price of drugs or medical supplies involved, return unreasonable income, etc , the practical measures to actively repair credit include terminating the relevant breach of trust, terminating the employment relationship with the employees involved, entrusting the agent enterprise, issuing the apology statement publicly, actively removing the false high space in the price of the products involved, correcting the unreasonable high price formed by the manipulation of the market and actively returning unreasonable income ,,《》3,,,《》(〔××××〕××),。 that is, since the "guidance on the establishment of drug prices and financial credit evaluation system" published, all non-compliance behavior of enterprises will be recorded by big data, and directly affect the credit evaluation of enterprises, the relevant departments also to the local liberalization of rights, encourage local exploration of more credit rating methods - all pharmaceutical companies involved Professor Jiang Bin of Peking University School of Pharmacy and Peking University Public Policy Research Center told the Chinese Health Journal that after accumulating sufficient drug prices and credit data, in the drug collection, the same conditions can be given priority and credit record better enterprise transactions, can also be the subject of rejection of the main body of rejection of transactions, improve trading conditions and other discipline, serious breach of trust enterprises are excluded from the public procurement market, can really establish honest yelling, fair competition, the survival of the market mechanism more and more documents on the treatment of pharmaceutical bribery and the promotion of rational drug use, which brings reflection and alarm to all pharmaceutical companies, agents and pharmaceutical representatives in it, academic promotion and pharmaceutical sales industry compliance, standardization will become the future trend.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.